1. Biosimilar Best Practice Day 21st January 2019 Ricoh Suite, Cardiff City Stadium
Procurement Services
Medicines (Acute) Sourcing Team
Tracey Prothero
Senior Category Manager

2. Medicines (Acute) Sourcing Team
Currently a team of 5 people
All Wales contract expenditure of £170m (£315m)
2,602 drug lines (25 Framework Contracts)
131 suppliers
Savings opportunities created during 2017/18 - £12.1m

3. Contract Cycle Demand Manage and Review Tender Process
Analysis
Standstill/ Award Process
Contract Implementation
Manage and Review

4. Chief Pharmacists Group
Welsh Government
Chief Pharmaceutical Officer
Health Boards and Velindre Cancer Centre
Chief Pharmacists Group
NHS Wales Shared Services Partnership
Director Procurement Services
All Wales Drug Contracting Committee
All Wales Medicines Procurement Specialist Pharmacist
All Wales Quality Control and Assurance Pharmacist
NWSSP Procurement Services Acute Medicine Team
Welsh Medicines Procurement and Logistics Advisory Group
Clinical Pharmaceutical Technical Services Group
Service Users
Suppliers

5. All Wales saving achieved to date: £17.5m
Biosimilar Contracts
Contracts for the following Biosimilar drugs have been agreed since 2015:
Infliximab,
Etanercept,
Rituximab,
Trastuzumab
Adalimumab
All Wales saving achieved to date: £17.5m

6. Things to consider when tendering
Engagement with other home nations
Optimum number of contractors
Homecare requirement
Data Quality
Device for administration
Continuity of supply
Licensed indications of biosimilar products vs originator product
Differing excipients vs originator
Consensus meetings – who to involve?

7. Contract Management Usage monitoring Price benchmarking
Ongoing savings reports
Homecare - Monitoring Monthly KPI data
Regular contract review meetings/Price reviews

8. What Next? Horizon Scanning
Improving Communication and links with clinical teams
Take Learning from previous projects to improve and develop future agreements

9. Questions?